Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib.

European thyroid journal - 1 Oct 2024

Gambale Carla, Prete Alessandro, Romei Chiara, Celi Alessandro, Elisei Rossella, Matrone Antonio

Abstract excerpt

Highly selective RET inhibitor selpercatinib has demonstrated notable efficacy in advanced/progressive RET-mutant medullary thyroid cancer (MTC) patients. However, despite a more tolerable toxicity profile than multikinase inhibitors, peculiar adverse events (AEs) have been described. Obliterative bronchiolitis (OB) is a respiratory disease characterized by inflammation and fibrosis in small conducting airways....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Neuroendocrine

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39136571
DOI: 10.1530/ETJ-24-0189
PMCID: PMC11466268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib.PMID 39136571Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.Semantic proximity Read ↗

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS MetastasesSemantic proximity Read ↗

Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over timeSemantic proximity Read ↗

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.Semantic proximity Read ↗

Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.Semantic proximity Read ↗

Management of medullary thyroid cancer.Semantic proximity Read ↗

Sustained Response with Dose Reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid CarcinomaSemantic proximity Read ↗

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.